Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: An in vitro and in vivo study

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 1955-1962

  Lu, Cui Tao ^a   Jin, Rong Rong ^a   Jiang, Yi Na ^a   Lin, Qian ^a   Yu, Wen Ze ^a   Mao, Kai Li ^a   Tian, Fu Rong ^a   Zhao, Ya Ping ^a   Zhao, Ying Zheng ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

6 hydroxydopamine; Apoptosis; Gelatin nanoparticles; Intranasal delivery; Parkinson s disease; Substance P

Indexed keywords

CASPASE 3; GELATIN; GELATIN NANOPARTICLE; NANOPARTICLE; OXIDOPAMINE; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ENCAPSULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RESPONSE; DRUG STABILITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MTT ASSAY; NEUROPROTECTION; NONHUMAN; PARKINSONISM; RAT; SUBSTANTIA NIGRA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PC12 CELL LINE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, INTRANASAL; ANIMALS; APOPTOSIS; CASPASE 3; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GELATIN; MALE; MOLECULAR STRUCTURE; NANOPARTICLES; OXIDOPAMINE; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE P; SUBSTANTIA NIGRA;

EID: 84929169578     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S77237     Document Type: Article

References (38)

1. Barbiero JK, Santiago R, Tonin FS, et al. PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53: 35–44.
2. Fujita H, Ogino T, Kobuchi H, et al. Cell-permeable cAMP analog suppresses 6-hydroxydopamine-induced apoptosis in PC12 cells through the activation of Akt pathway. Brain Res. 2006;1113:10–23.
3. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson’s disease. Antioxid Redox Signal. 2005;7:685–693.
4. Li X, Ye X, Li X, et al. Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway. Brain Res. 2011; 1382:9–18.
5. Fiebich BL, Schleicher S, Butcher RD, Craig A, Lieb K. The neuropeptide substance P activates p38 mitogen-activated protein kinase resulting in IL-6 expression independently from NF-kappa B. J Immunol. 2000;165:5606–5611.
6. Betaret R, Greenamyre JT. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol. 2004;189:393–403.
7. Chen LW, Yung KK, Chan YS. Neurokinin peptides and neurokinin receptors potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson’s disease. Curr Drug Targets. 2004;5:197–206.
8. Thornton E, Tran TT, Vink R. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death. Neurosci Lett. 2010;481:64–67.
9. Backman LJ, Danielson P. Akt-mediated anti-apoptotic effects of substance P in Anti-Fas-induced apoptosis of human tenocytes. J Cell Mol Med. 2013;17:723–733.
10. Jiang MH, Lim JE, Chi GF, et al. Substance P reduces apoptotic cell death possibly by modulating the immune response at the early stage after spinal cord injury. Neuroreport. 2013;24:846–851.
11. Krasnova IN, Bychkov ER, Lioudyno VI, Zubareva OE, Dambinova SA. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience. 2000;95:113–117.
12. Nikolaus S, Huston JP, Schwarting PK. Pretreatment with fragments of substance P or with cholecystokinin differential affects recovery from sub-total nigrostriatal 6-hydroxydopamine lesion. Neural Plast. 1999;6:77–89.
13. Thornton E, Vink R. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson’s disease. PLoS One. 2012;7:e34138.
14. Thornton E, Ziebell JM, Leonard AV, Vink R. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules. 2010;15:6598–6618.
15. Weinstock JV. Substance P and the regulation of inflammation in infections and inflammatory bowel disease. Acta Physiol (Oxf). 2015;213:453–461.
16. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614–628.
17. Sivera M, Kvitek L, Soukupova J, et al. Silver nanoparticles modified by gelatin with extraordinary pH stability and long-term antibacterial activity. PLoS One. 2014;9:e103675.
18. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. J Control Release. 2013;172:1075–1091.
19. Lee SJ, Yhee JY, Kim SH, Kwon IC, Kim K. Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice. J Control Release. 2013;172:358–366.
20. Varshosaz J, Eskandari S, Tabbakhian M. Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design. Pharm Dev Technol. 2010;15:89–96.
21. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20:286–296.
22. Zare K, Eidi A, Roghani M, Rohani AH. The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat. Metab Brain Dis. 2015;30:205–213.
23. Suzuki S, Kawamata J, Iwahara N, et al. Intravenous mesenchymal stem cell administration exhibits therapeutic effects against 6-hydroxydopamine-induced dopaminergic neurodegeneration and glial activation in rats. Neurosci Lett. 2015;584:276–281.
24. Zhang X, Zhu Y, Duan W, Feng C, He X. Allicin induces apoptosis of the MGC-803 human gastric carcinoma cell line through the p38 mitogen-activated protein kinase/caspase-3 signaling pathway. Mol Med Rep. 2015;11:2755–2760.
25. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007;32:1054–1082.
26. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379:146–157.
27. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2:165–175.
28. Ahmad N, Umar S, Ashafaq M, et al. A comparative study of PNIPAM nanoparticles of curcumin, demethoxycurcumin, and bisdemethoxycurcumin and their effects on oxidative stress markers in experimental stroke. Protoplasma. 2013;250:1327–1338.
29. Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 2013;24:2101–2115.
30. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000;11:1–18.
31. Thorne RG, Frey WH 2nd. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001;40:907–946.
32. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99:1654–1673.
33. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337:1–24.
34. Di Colo G, Zambito Y, Zaino C. Polymeric enhancers of mucosal epithelia permeability: synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci. 2008;97:1652–1680.
35. Zaki NM, Awad GA, Mortada ND, Abd ElHady SS. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32:296–307.
36. Vandelli MA, Rivasi F, Guerra P, Forni F, Arletti R. Gelatin microspheres crosslinked with d,l-glyceraldehyde as a potential drug delivery system: preparation, characterization, in vitro and in vivo studies. Int J Pharm. 2001;215:175–184.
37. Zhao YZ, Li X, Lu CT, et al. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 2014;10:755–757.
38. Hu X, Zhang H, Zhang Y, et al. Differential protein profile of PC12 cells exposed to proteasomal inhibitor lactacystin. Neurosci Lett. 2014;575:25–30.